AVS Pulse

Executive Summary

AVS Pulse is a San Francisco-based medical device company developing Pulse IVL, a novel intravascular lithotripsy (IVL) system for treating calcified arterial disease. Founded in 2019, the company aims to address the significant challenge of limited treatment options for this widespread condition. Pulse IVL is designed to deliver efficient and easy-to-use therapy, differentiating itself through a unique energy delivery mechanism. Currently in the pre-clinical stage, AVS Pulse has not disclosed funding or valuation, highlighting its early and private status. The technology's promise lies in potentially improving outcomes for patients with complex calcified lesions, a large and growing market. However, the lack of clinical data and transparency introduces substantial uncertainty.

Upcoming Catalysts (preview)

• Q3 2026Completion of preclinical studies and IDE submission40% success
• Q2 2026Presentation of pivotal preclinical data at a major cardiology conference60% success
• Q1 2027Initiation of first-in-human clinical trial30% success